Agency: Cordis | Branch: FP7 | Program: CP-TP | Phase: KBBE.2012.3.3-03 | Award Amount: 7.11M | Year: 2012
The European Life science and chemical industries increasingly depend on effi-cient, sustainable, and cost-effective bioprocessing platforms to remain competi-tive. A critical assessment of current bottlenecks during (bio) manufacturing clearly indicates that the recovery and purification of biologicals in large scale in responsible for many inefficiencies. INTENSO proposes an evaluation of the current situation of the downstream processing scenario with the aim of identifying inefficiencies and concomitantly introduce a debottlenecking overarching strategy. The later will be build up on the basis of a multidisciplinary approach, which considers opportunities to im-prove the process technology and underlying chemistry / biology and materials science at the same time. INTENSO will work alongside 4 technological axes, targeting promising and up-coming technologies and tailoring such technologies to the manufacturing of various classes of (bio) products. Intensification of individual unit operations and global process integration, as well as, dovetailing with fermentation / cell cultivation will be employed to the mentioned end. INTENSO will target new classes of (bio) products like Monoclonal Antibodies (Mabs), pDNA (e.g. for genetic vaccination), Virus Like Particles (VLP) or nano-plexes. All the mentioned new products are part of most industrial R&D pipelines and offer an excellent opportunity to introduce innovative bioprocessing. The results of the project are expected to contribute to the understanding of current industrial downstream processing practice, to the definition and alleviation of current inefficiencies, to the development and / or implementation of novel technologies, and to more efficient / sustainable and cost effective (bio) manufacturing. Various technologies will be studied utilizing a nano-to-process strategy so as to introduce integration / intensification during bioprocessing.
Bia Separations D.O.O. | Date: 2002-12-17
[ Chemicals for use in the manufacture of chromatographic devices; and polymers and monomers for use in the pharmaceutical, biotechnology, chemical and [ medical ] * MEDICINAL * industries; chemicals, namely, rigid porous polymer of monolithic structure for the separation and purification of mixtures for the separation and purification of mixtures, isolation of substances, chromatographic materials, artificial porous resins for chromatographic purposes for use in the pharmaceutical and biotechnology industries ]. Liquid chromatography apparatus, namely, monolithic devices for samples to be analyzed and purified; scientific apparatus, namely, instruments for the separation and purification of mixtures, isolation of substances; compact porous discs and tubes of artificial porous resins in columns and cartridges for the separation and purification of mixtures, isolation of substances; kits containing chemicals, namely monolithic devices for the separation and purification of mixtures, isolation of substances, chromatographic materials, artificial porous resins for chromatographic purposes, compact porous discs and tubes of artificial porous resins in columns * AND * cartridges for the separation and purification of mixtures, isolation of substances for use in the pharmaceutical, biotechnology, * CHEMICAL * and medicinal industries. [ * LIQUID * chromatography apparatus for industrial use ].
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.1-1 | Award Amount: 7.80M | Year: 2011
Glycosylation is a post-translational modification that enriches protein complexity and function. Dysregulation of glycosylation is associated with a wide range of diseases, including cancer, diabetes, as well as congenital, cardiovascular, immunological and infectious disorders. A number of studies identified potentially important glycan disease biomarkers. With regard to biotechnology, proper glycosylation of biologicals is important, as deviations in glycosylation are known to be associated with adverse drug reactions and reduced therapeutic efficacy. However, glycomics is significantly lagging behind genomics and proteomics, mainly due to the absence of high-throughput analytical methods which can reliably quantify a multitude of glycan structures in complex biological samples. We are confident that by coordinated efforts of leading European scientists in glycan analysis using HPLC, MS and CGE-LIF technologies this project will make a decisive step forward by developing real high-throughput tools for glycosylation analysis. By teaming up with leading European researchers in the field of genome wide association studies this project will perform validation of all methods on extremely well characterized set of samples resulting from the FP6 EuroSpan project. The addition of the newly generated glycome data to the pre-existing information about these individuals will enable development of methods for the systems biology approach analysis of the glycome which will integrate glycomic, genomic and environmental data about thousands of individuals. The same methods will also be adapted for quality control and monitoring in the production of biopharmaceuticals. Strong participation of SMEs in the project and close contacts with large industrial partners will ensure that research accomplishments achieved by collaboration between academic and industrial scientists are swiftly transformed into innovative products and services for the benefit of European industry.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.1-3 | Award Amount: 3.21M | Year: 2011
The main objective of the proposed collaborative project Prot-HiSPRA is to remove time-consuming bottlenecks of existing proteomics technologies (sample preparation, fractionation, proteolysis, separation, data collection, and data mining) and bring the proteome driven analysis into time sensitive clinical practice. Prot-HiSPRA is an objective-driven research project and it aims at generating new knowledge and new technologies which will improve the European competitiveness in the field of applied proteomics. Prot-HiSPRA is planned for the duration of 36 months which is necessary in order to ensure a high-quality validation of the developed high-throughput methodologies. A strong participation of SMEs (partner 2 MAYLAB, partner 3 CELS - left the onsortium, partner 6 RTDs, partner 7 - BIA) will ensure strong innovation and exploitation during HiSPRA. Research activities in the Prot-HiSPRA program can be divided into a technological core project that is tailored to significantly improve on technologies in the fields of proteomics, bioinformatics, and integrated biology. Analytical methods developed with the Prot-HiSPRA project will be exemplified by applying for analysis of clinical samples originating from in vitro fertilization (IVF) procedures. During the IVF process, especially at the moment when decisions are made which embryo can be implanted, decisions must be made so that the process has the greatest chance for success. To further elevate pregnancy rates for IVF a non-invasive, rapid, and robust methods for judging the embryos status is urgently needed to examine the embryos proteome. These methods could not only be applied in the described field of reproductive medicine but also in any the other fields of clinical analysis where fast and reliable diagnosis on a proteomic basis could be made available.
Agency: Cordis | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2012-IAPP | Award Amount: 1.82M | Year: 2013
The main aim of the HTP-GlycoMet proposal is to develop technologies, which will enable high-throughput analysis of glycosylation of individual proteins from body fluids and cell membranes and apply them to understand some key processes in immunity and infections. Glycan analysis is extremely demanding from both technological and conceptual aspect and (beside one study performed by partners in this proposal) large-scale studies of glycosylation of individual proteins were not attempted previously. However, we are confident that by successfully combining complementary expertise in the (i) production of specialised monolithic chromatographic tools for high-throughput fractionation of complex biological fluids (BIA-SEP), (ii) purification of proteins from body fluids and membrane proteins (UNI-RI), (iii) high-throughput glycomic analysis by use of chromatography (Genos) and multiplexed capillary gel electrophoresis (MPI) and (iv) expertise in the field of viral immunology (MEDRI) we can achieve significant progress in this direction. All our partners are recognized leaders who already made significant progress beyond the state of the art in their respective fields. Through HTP-GlycoMet project we will organise secondments on all levels (MER, ER, ESR) to capitalize on synergistic effects of this interdisciplinary and transnational collaboration. In addition to the generation of new knowledge and the development of new innovative technologies, we will also achieve significant transfer of knowhow between academic and industrial partners. Our SME partners also expect to develop new lines of products and services through the HTP-GlycoMet programme, but also through future collaboration with HTP-GlycoMet partners beyond the lifetime of this project.